Non-invasive assessment of bone density in primary biliary cirrhosis

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 3, 1999, Pages 323-328

  Pereira, Stephen P ^a   Bray, Gary P ^a   Pitt, Pauline I ^a   Li, Famei ^a   Moniz, Caje ^a   Williams, Roger ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Bone biochemical markers; Bone densitometry; Osteopenia; Osteoporosis; Primary biliary cirrhosis

Indexed keywords

CREATININE; DEOXYPYRIDINOLINE; MARKER; PEPTIDE; PROCOLLAGEN; PYRIDINOLINE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; DEGRADATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; HIP; HUMAN; LEAN BODY WEIGHT; LUMBAR SPINE; MOBILIZATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RISK; URINE LEVEL;

EID: 0033033389     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199903000-00018     Document Type: Article

References (53)

1. Hay JE. Bone disease in cholestatic liver disease. Gastroenterology 1995; 108:276-283.
2. Rosen H. Primary biliary cirrhosis and bone disease. Hepatology 1995; 21:253-255.
3. Guanabens N, Pares A, Marinoso L, Brancos MA, Piera C, Serrano S, et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990; 85:1356-1362.
4. Hodgson SF, Dickson ER, Wahner HW, Johnson KA, Mann KG, Riggs BL. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985; 103:855-860.
5. Cuthbert JA, Pak CY, Zerwekh JE, Glass KD, Combes B. Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 1984; 4:1-8.
6. Shih MS, Anderson C. Does 'hepatic osteodystrophy' differ from peri-and postmenopausal osteoporosis? A histomorphometric study. Calcif Tissue Int 1987; 41:187-191.
7. Compston JE, Cooper C, Kanis JA. Bone densitometry in clinical practice. BMJ 1995; 310:1507-1510.
8. Delmas PD, Demiaux B, Malaval L, Chapuy MC, Edouard C, Meunier RJ. Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry. J Clin Invest 1986; 77:985-991.
9. Parfitt AM, Simon LS, Villanueva AR, Krane SM. Procollagen type I carboxyterminal extension peptide in serum as a marker of collagen biosynthesis in bone: correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987; 2:427-436.
10. Delmas PD, Schlemmer A, Gineyts E, Riis B, Christiansen C. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 1991; 6:639-644.
11. Robins SP, Duncan A. Pyridinium crosslinks of bone collagen and their location in peptides isolated from rat femur. Biochim Biophys Acta 1987; 914:233-239.
12. Kaplan M.M. Primary biliary cirrhosis. N Engl J Med 1996; 335:1570-1580.
13. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10:1-7.
14. Klion FM, Fabry TL, Palmer M, Schaffner F. Prediction of survival of patients with primary biliary cirrhosis. Examination of the Mayo Clinic model on a group of patients with known endpoint. Gastroenterology 1992; 102:310-313.
15. Portmann B, Popper H, Neuberger J, Williams R. Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients. Gastroenterohgy 1985; 88:1777-1790.
16. Suleiman S, Nelson M, Li F, Buxton-Thomas M, Moniz C. Effect of calcium intake and physical activity level on bone mass and turnover in healthy, white, postmenopausal women. Am J Clin Nutr 1997; 66:937-943.
17. Kanis JA, Melton L Jr, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9:1137-1141.
18. Javaid A. Performance characteristics of a dual energy X-ray absorptiometer and patterns of recovery in anorexia nervosa. PhD thesis: University of London, 1991.
19. Bingham CT, Fitzpatrick LA. Noninvasive testing in the diagnosis of osteomalacia. Am J Med 1993; 95:519-523.
20. Li F, Iqbal J, Wassif W, et al. Carboxyterminal propeptide of type I procollagen in osteomalacia. Calcif Tissue Int 1994; 55:90-93.
21. Risteli J, Niemi S. Trivedi P, Maentausta O. Mowat AP, Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem 1988; 34:715-718.
22. Power MJ, Fottrell PF. Solid-phase enzymoimmunoassay for osteocalcin in human serum or plasma, with use of a monoclonal antibody. Clin Chem 1989; 35:2087-2092.
23. Li F, Pitt PI, Sherwood R, Barrett J, Houghton J, Parsons V, Moniz C. Biochemical markers of bone turnover in women with surgically treated carcinoma of the breast. Eur J Clin Invest 1993; 23:566-571.
24. Eastell R, Dickson ER, Hodgson SF, Wiesner RH, Porayko MK, Wahner HW, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991; 14:296-300.
25. Van Berkum FN, Beukers R, Birkenhager JC, Kooij PP, Schalm SW, Pols HA. Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids. Gastroenterology 1990; 9:1134-1139.
26. Uebelhart D, Gineyts E, Chapuy M-C, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990; 8:87-96.
27. Tsuneoka K, Tameda Y, Takase K, Nakano T. Osteodystrophy in patients with chronic hepatitis and liver cirrhosis. J Gastroenterol 1996; 31:669-678.
28. Stellon AJ, Webb A, Compston J, Williams R. Low bone turnover state in primary biliary cirrhosis. Hepatology 1987; 7:137-142.
29. Wang JC, Aung MK, Tobin MS. Urinary hydroxyproline excretion in myelofibrosis. Blood 1980; 55:383-385.
30. Ng TP, Jones MG, Pang CP, Chan SL. Fasting urinary hydroxyproline: creatlnine ratios in silicosis. Ann Acad Med Singapore 1989; 18:692-695.
31. Bonkovsky HL, Hawkins M, Steinberg K, Hersh T, Galambos JT, Henderson JM, et al. Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 1990; 12:273-280.
32. Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL. Role of hyperbilirublnemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995; 95:2581-2586.
33. Kaplan MM, Elta GH, Furie B, Sadowski JA, Russell RM. Fat-soluble vitamin nutriture in primary biliary cirrhosis. Gastroenterology 1988; 95:787-792.
34. 1 level is decreased in primary biliary cirrhosis. Am J Gastroenterol 1997; 92:2059-2061.
35. Plantalech L, Guillaumont M, Vergnaud P, Leclercq M, Delmas PD. Impairment of gamma carboxylation of circulating osteocalcin (bone Gla protein) in elderly women. J Bone Miner Res 1991; 6:1211-1216.
36. Szulc P, Chapuy MC, Meunier PJ, Delams PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 1993; 91:1769-1774.
37. Hara K, Akiyama Y, Nakamura T, Murota S, Morita I. The inhibitory effect of vitamin K2 (menatetrenone) on bone resorption may be related to its side chain. Bone 1995; 16:179-184.
38. Stellon AJ, Webb A, Compston J, Williams R. Lack of osteomalacia in chronic cholestatic liver disease. Bone 1986; 7:181-185.
39. Floreani A, Chiaramonte M, Giannini S, Malvasi L, Lodetti MG, Castrignano R, et al. Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study on calcitonin treatment. J Hepatol 1991; 2:217-223.
40. Camisasca M, Crosignani A, Battezzati PM, Albisetti W, Grandinetti G, Pietogrande L, et al. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994; 20:633-637.
41. Prince RL, Smith M, Dick IM, Price RI, Webb PG, Henderson NK, Harris MM. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 1991; 325:1189-1195.
42. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437-1443.
43. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross PD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Wed 1993; 95:557-567.
44. Wolfhagen FH, van Buuren HR, den Ouden JW, Hop WC, van Leeuwen JP, Schalm SW, Pols HA. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis: a prospective controlled pilot study. J Hepatol 1997; 26:325-330.
45. Chow J, Tobias JH, Colston KW, Chamber TJ. Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. J Clin Invest 1992; 89:74-78.
46. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117:1-9.
47. Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. N Engl J Med 1993; 327:620-627.
48. Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead MI. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 336:265-269.
49. Lindsay R. Prevention and treatment of osteoporosis. Lancet 1993; 341:801-805.
50. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 25:1769-1775.
51. Crippin JS, Jorgensen RA, Dickson ER, Lindor KD. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994; 89:47-50.
52. van Erpecum KJ, van Berge Henegouwen GP, Verschoor L, Stoeiwinder B, Willekens FL. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausai women. Gastroenterology 1991; 100:482-488.
53. O'Donohue J, Williams R. Hormone replacement therapy in women with liver disease. Br J Obstet Gynaecol 1997; 104:1-3.